NLS Pharmaceutics & Kadimastem Merger Conditions Met
Ticker: NCEL · Form: 6-K · Filed: Oct 28, 2025 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Oct 28, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: merger, acquisition, delisting
TL;DR
NLS Pharma merger conditions met, Kadimastem shares delisting soon.
AI Summary
On October 28, 2025, NLS Pharmaceutics Ltd. announced the completion of material conditions precedent for its merger with Kadimastem. This announcement also confirmed the delisting date for Kadimastem's shares.
Why It Matters
This filing indicates progress towards a significant corporate transaction, potentially impacting the future structure and operations of NLS Pharmaceutics.
Risk Assessment
Risk Level: medium — Merger transactions carry inherent risks related to integration, regulatory approval, and market reception.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant and party to merger
- Kadimastem (company) — Company merging with NLS Pharmaceutics
- October 28, 2025 (date) — Date of press release and announcement
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose is to report a press release announcing the completion of material conditions precedent for the merger between NLS Pharmaceutics Ltd. and Kadimastem, and the delisting date of Kadimastem's shares.
Who are the main companies involved in the transaction mentioned?
The main companies involved are NLS Pharmaceutics Ltd. and Kadimastem.
When was the press release announcing these developments issued?
The press release was issued on October 28, 2025.
What is the significance of 'completion of material conditions precedent'?
It means that key requirements or stipulations necessary for the merger transaction to proceed have been fulfilled.
What action is being taken regarding Kadimastem's shares?
Kadimastem's shares are scheduled for delisting, as announced in the press release.
Filing Stats: 218 words · 1 min read · ~1 pages · Grade level 12 · Accepted 2025-10-28 16:37:59
Filing Documents
- ea0262869-6k_nlspharma.htm (6-K) — 17KB
- ea026286901ex99-1_nlspharma.htm (EX-99.1) — 13KB
- 0001213900-25-103130.txt ( ) — 31KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: October 28, 2025 By: /s/ Alexander C. Zwyer Name: Alexander C. Zwyer Title: Chief Executive Officer 2